Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer
-
Published:2023-08
Issue:8
Volume:41
Page:354.e1-354.e9
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Fan JunjieORCID,
Liang Hua,
Gu Yanan,
Jiang Zhangdong,
Jiang Fan,
Wang Yingchun,
He Dalin,
Wu Kaijie
Reference27 articles.
1. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide;Hassanipour-Azgomi;Prostate Int,2016
2. Time trends and local variation in primary treatment of localized prostate cancer;Cooperberg;J Clin Oncol,2010
3. Predicting 15-year prostate cancer specific mortality after radical prostatectomy;Eggener;J Urol,2011
4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献